ISSN: ISSN 2472-0429

Progrès dans la prévention du cancer

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Anti-virus {virus COVID-19}: Yes! Were used to Resolve it as a Cancer Problem. It Works for Ebola

Winston Vo

When viruses infect host cells or organs, the dysfunction of these parts (or tumors) is a result. We name it “a tumor” then we tackle it as a cancer issue! Very straightforward: it works for Ebola.

We have options in oncology: Surgery, Radiation, Chemotherapy, and Immunotherapy. Depending on the rate of its spread, we use one or a combination of those treatments. The rate of success depends on the stage (spread of tumors).

Infection with COVID-19 often causes a severe acute respiratory syndrome. We could consider it as a lung cancer, and treatment plans for it are already well-established in the field of oncology. It’s a virus, so the patient should be considered a candidate for treatment with immunotherapy (or vaccines) based on our body’s defense against cancer.